Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Identification and characterization of tumor-initiating cells in human primary cutaneous squamous cell carcinoma.

Patel GK, Yee CL, Terunuma A, Telford WG, Voong N, Yuspa SH, Vogel JC.

J Invest Dermatol. 2012 Feb;132(2):401-9. doi: 10.1038/jid.2011.317. Epub 2011 Oct 20.

2.

Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells.

Zhang H, Cui Y, Voong N, Sabatino M, Stroncek DF, Morisot S, Civin CI, Wayne AS, Levine BL, Mackall CL.

J Immunother. 2011 Mar;34(2):187-95. doi: 10.1097/CJI.0b013e31820d2a21.

3.

Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17.

Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, Berzofsky JA, Wakefield LM.

Cancer Res. 2008 May 15;68(10):3915-23. doi: 10.1158/0008-5472.CAN-08-0206.

4.

Transforming growth factor-beta1 sensitivity is altered in Abl-Myc- and Raf-Myc-induced mouse pre-B-cell tumors.

Letterio J, Rudikoff E, Voong N, Bauer SR.

Stem Cells. 2006 Dec;24(12):2611-7. Epub 2006 Aug 31.

5.

The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells.

Liby K, Voong N, Williams CR, Risingsong R, Royce DB, Honda T, Gribble GW, Sporn MB, Letterio JJ.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4288-93.

Supplemental Content

Support Center